Treatment of metastatic hormone‐sensitive prostate cancer

Background: Adaptive upregulation of Androgen Receptor (AR) is the most common event involved in the progression from hormone sensitive to Castration-Resistant Prostate Cancer (CRPC). AR signaling remains the main target of new AR signalling-directed therapies such as abiraterone and enzalutamide in CRPC patients. Objective: In this review, we discuss general mechanisms of resistance to AR-targeted therapies, with a focus on the role of AR Copy Number (CN). We reported methods and clinical applications of AR CN evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker. Conclusion: Outcomes of CRPC patients are reported to be highly variable as the consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.

Download Full-text

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-021-00389-2 ◽

2021 ◽

Author(s):

Daniel E. Lage ◽

M. Dror Michaelson ◽

Richard J. Lee ◽

Joseph A. Greer ◽

Jennifer S. Temel ◽

...

Keyword(s):

Prostate Cancer ◽

Older Men ◽

Hormone Sensitive

Download Full-text

Efficacy and adverse events of docetaxel for metastatic, hormone-sensitive prostate cancer among elderly men: post-hoc analysis of CHAARTED trial

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.03.016 ◽

2021 ◽

Author(s):

Eric V. Li ◽

Mohammad R. Siddiqui ◽

Adam B. Weiner ◽

Anna E. Prizment ◽

Charles J. Ryan ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Elderly Men ◽

Post Hoc Analysis ◽

Hormone Sensitive ◽

Post Hoc

Download Full-text

Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.03.022 ◽

2021 ◽

Author(s):

Rémi Pelloux-Prayer ◽

Philomène Schiele ◽

Stéphane Oudard ◽

Gwenaëlle Gravis ◽

François Kleinclauss ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Metastatic Prostate Cancer ◽

Cost Effectiveness Analysis ◽

Newly Diagnosed ◽

Innovative Therapy ◽

Effectiveness Analysis ◽

Hormone Sensitive

Download Full-text

Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer

Expert Review of Precision Medicine and Drug Development ◽

10.1080/23808993.2021.1863781 ◽

2020 ◽

pp. 1-9

Author(s):

Jürgen E Gschwend ◽

Kurt Miller

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Hormone Sensitive

Download Full-text

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

BMC Cancer ◽

10.1186/s12885-021-08206-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Teppei Okamoto ◽

Daisuke Noro ◽

Shingo Hatakeyama ◽

Shintaro Narita ◽

Koji Mitsuzuka ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Abiraterone Acetate ◽

Tumor Burden ◽

Hazard Ratio ◽

Historical Cohort ◽

High Tumor Burden ◽

Significant Difference ◽

Hormone Sensitive ◽

The Impact

Abstract Background Anemia has been a known prognostic factor in metastatic hormone-sensitive prostate cancer (mHSPC). We therefore examined the effect of anemia on the efficacy of upfront abiraterone acetate (ABI) in patients with mHSPC. Methods We retrospectively evaluated 66 mHSPC patients with high tumor burden who received upfront ABI between 2018 and 2020 (upfront ABI group). We divided these patients into two groups: the anemia-ABI group (hemoglobin < 13.0 g/dL, n = 20) and the non-anemia-ABI group (n = 46). The primary objective was to examine the impact of anemia on the progression-free survival (PFS; clinical progression or PC death before development of castration resistant PC) of patients in the upfront ABI group. Secondary objectives included an evaluation of the prognostic significance of upfront ABI and a comparison with a historical cohort (131 mHSPC patients with high tumor burden who received androgen deprivation therapy (ADT/complete androgen blockade [CAB] group) between 2014 and 2019). Results We found that the anemia-ABI group had a significantly shorter PFS than the non-anemia-ABI group. A multivariate Cox regression analysis showed that anemia was an independent prognostic factor of PFS in the upfront ABI group (hazard ratio, 4.66; P = 0.014). Patients in the non-anemia-ABI group were determined to have a significantly longer PFS than those in the non-anemia-ADT/CAB group (n = 68) (P < 0.001). However, no significant difference was observed in the PFS between patients in the anemia-ABI and the anemia-ADT/CAB groups (n = 63). Multivariate analyses showed that upfront ABI could significantly prolong the PFS of patients without anemia (hazard ratio, 0.17; P < 0.001), whereas ABI did not prolong the PFS of patients with anemia. Conclusion Pretreatment anemia was a prognostic factor among mHSPC patients who received upfront ABI. Although the upfront ABI significantly improved the PFS of mHSPC patients without anemia, its efficacy in patients with anemia might be limited.

Download Full-text